Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).

Article  CAS  PubMed  Google Scholar 

Chang, J. C. HER2 inhibition: from discovery to clinical practice. Clin. Cancer Res. 13, 1–3 (2007).

Article  PubMed  Google Scholar 

Leavy, O. Therapeutic antibodies: past, present and future. Nat. Rev. Immunol. 10, 297–297 (2010).

Article  CAS  PubMed  Google Scholar 

Di Fiore, P. P. et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237, 178–182 (1987).

Article  PubMed  Google Scholar 

Fendly, B. M. et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50, 1550–1558 (1990).

CAS  PubMed  Google Scholar 

Hancock, M. C. et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 51, 4575–4580 (1991).

CAS  PubMed  Google Scholar 

Harwerth, I. M., Wels, W., Schlegel, J., Müller, M. & Hynes, N. E. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br. J. Cancer 68, 1140–1145 (1993).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drebin, J. A., Link, V. C., Stern, D. F., Weinberg, R. A. & Greene, M. I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41, 697–706 (1985).

Article  CAS  PubMed  Google Scholar 

Lewis, G. D. et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37, 255–263 (1993).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shak, S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin. Oncol. 26, 71–77 (1999).

CAS  PubMed  Google Scholar 

Cobleigh, M. A. et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639 (1999).

Article  CAS  PubMed  Google Scholar 

Baselga, J. et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14, 737–744 (1996).

Article  CAS  PubMed  Google Scholar 

Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).

Article  CAS  PubMed  Google Scholar 

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet. Oncol. 22, 1139–1150 (2021).

Article  Google Scholar 

Oh, D. Y. & Bang, Y. J. HER2-targeted therapies – a role beyond breast cancer. Nat. Rev. Clin. Oncol. 17, 33–48 (2020).

Article  CAS  PubMed  Google Scholar 

Yarden, Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 37, 3–8 (2001).

Article  Google Scholar 

Moasser, M. M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26, 6469–6487 (2007).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).

Article  CAS  PubMed  Google Scholar 

Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat. Rev. Drug. Discov. 22, 101–126 (2023).

Article  CAS  PubMed  Google Scholar 

Mandó, P., Rivero, S. G., Rizzo, M. M., Pinkasz, M. & Levy, E. M. Targeting ADCC: a different approach to HER2 breast cancer in the immunotherapy era. Breast 60, 15–25 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Junttila, T. T., Li, G., Parsons, K., Phillips, G. L. & Sliwkowski, M. X. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res. Treat. 128, 347–356 (2011).

Article  CAS  PubMed  Google Scholar 

Ogitani, Y., Hagihara, K., Oitate, M., Naito, H. & Agatsuma, T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 107, 1039–1046 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rugo, H. S. et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 7, 573–584 (2021).

Article  PubMed  Google Scholar 

Tarantino, P. et al. Margetuximab for the treatment of HER2-positive metastatic breast cancer. Expert. Opin. Biol. Ther. 21, 127–133 (2021).

Article  CAS  PubMed  Google Scholar 

Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 21, 519–530 (2020).

Article  CAS  PubMed  Google Scholar 

Tarantino, P. et al. Aiming at a tailored cure for ERBB2-positive metastatic breast cancer: a review. JAMA Oncol. 8, 629–635 (2022).

Article  PubMed  Google Scholar 

Costa, R. L. B. & Czerniecki, B. J. Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. NPJ Breast Cancer 6, 10 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tarantino, P. et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J. Clin. 72, 165–182 (2021).

Article  PubMed  Google Scholar 

Mosele, F. et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat. Med. 29, 2110–2120 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tarcsa, E., Guffroy, M. R., Falahatpisheh, H., Phipps, C. & Kalvass, J. C. Antibody-drug conjugates as targeted therapies: are we there yet? A critical review of the current clinical landscape. Drug. Discov. Today.: Technol. 37, 13–22 (2020).

Article  PubMed  Google Scholar 

Colombo, R., Barnscher, S. D. & Rich, J. R. Revisiting the dogma of antibody drug conjugates (ADCs): emerging data challenge the benefit of linker stability and the primacy of payload delivery [abstract]. Cancer Res. 83 (Suppl. 7), 1538 (2023).

Article  Google Scholar 

Pohlmann, P. R., Mayer, I. A. & Mernaugh, R. Resistance to trastuzumab in breast cancer. Clin. Cancer Res. 15, 7479–7491 (2009).

Article  CAS  PubMed  PubMed Central